11496 related articles for article (PubMed ID: 1293168)
1. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
Horikoshi T; Ito S
J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of melanin-related metabolites as markers of melanoma progression.
Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
[TBL] [Abstract][Full Text] [Related]
3. Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression.
Wakamatsu K; Ito S; Horikoshi T
Melanoma Res; 1991; 1(2):141-7. PubMed ID: 1823626
[TBL] [Abstract][Full Text] [Related]
4. 5-S-cysteinyldopa in urine and tumors.
Hara H; Chino K; Kawanami T; Sameshima T; Morishima T
J Dermatol; 1992 Nov; 19(11):806-8. PubMed ID: 1293167
[TBL] [Abstract][Full Text] [Related]
5. Production, circulation, and excretion of melanin-related metabolites in B16 melanoma-bearing mice.
Wakamatsu K; Ito S; Fujita K
Acta Derm Venereol; 1990; 70(5):367-72. PubMed ID: 1980967
[TBL] [Abstract][Full Text] [Related]
6. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
[TBL] [Abstract][Full Text] [Related]
8. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
Sameshima T; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
[TBL] [Abstract][Full Text] [Related]
9. Serum concentration of 5-S-cysteinyldopa in patients with melanoma.
Bánfalvi T; Gilde K; Boldizsár M; Fejös Z; Horváth B; Liszkay G; Beczássy E; Kremmer T
Eur J Clin Invest; 2000 Oct; 30(10):900-4. PubMed ID: 11029605
[TBL] [Abstract][Full Text] [Related]
10. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.
Omodaka T; Minagawa A; Uhara H; Wakamatsu K; Koizumi T; Yokokawa Y; Koga H; Okuyama R
J Dermatol; 2018 Nov; 45(11):1340-1344. PubMed ID: 30144152
[TBL] [Abstract][Full Text] [Related]
11. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma.
Kärnell R; Kågedal B; Lindholm C; Nilsson B; Arstrand K; Ringborg U
Melanoma Res; 2000 Aug; 10(4):363-9. PubMed ID: 10985671
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
13. Seasonal variation in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in healthy Japanese.
Wakamatsu K; Ito S
Pigment Cell Res; 1995 Jun; 8(3):132-4. PubMed ID: 7567788
[TBL] [Abstract][Full Text] [Related]
14. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1).
Ye Z; Kageshita T; Ishihara T; Ito S; Ono T
J Dermatol; 1995 May; 22(5):370-5. PubMed ID: 7673560
[TBL] [Abstract][Full Text] [Related]
15. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
[TBL] [Abstract][Full Text] [Related]
16. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S
Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma.
Bánfalvi T; Gilde K; Boldizsár M; Kremmer T
Neoplasma; 2002; 49(2):121-5. PubMed ID: 12088105
[TBL] [Abstract][Full Text] [Related]
18. [5-S-cysteinyldopa as a tumor marker for primary uveal malignant melanoma].
Goto H; Tenou T; Kudo H; Iwasaki T; Muramatsu R; Usui M; Wakamatsu K; Ito S
Nippon Ganka Gakkai Zasshi; 1998 May; 102(5):319-26. PubMed ID: 9619024
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients.
Sasaki Y; Shimizu H; Naka W; Takeshita E; Nishikawa T
Acta Derm Venereol; 1997 Sep; 77(5):379-81. PubMed ID: 9298132
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.
Bánfalvi T; Gilde K; Boldizsár M; Kremmer T; Ottó S
Pathol Oncol Res; 1999; 5(3):218-22. PubMed ID: 10491021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
